Financhill
Sell
26

QDEL Quote, Financials, Valuation and Earnings

Last price:
$35.36
Seasonality move :
6.89%
Day range:
$35.94 - $36.98
52-week range:
$29.74 - $49.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.88x
P/B ratio:
0.83x
Volume:
672K
Avg. volume:
935K
1-year change:
-21.99%
Market cap:
$2.5B
Revenue:
$2.8B
EPS (TTM):
-$30.28

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
QDEL
QuidelOrtho
$697M $0.58 -1.93% 480.41% $51.14
AEMD
Aethlon Medical
-- -$0.20 -100% -84.98% $3.88
CATX
Perspective Therapeutics
$267.3K -$0.25 -- -41.72% $15.58
VNRX
VolitionRX
$545.3K -$0.05 123.53% -51.52% $3.37
VTAK
Catheter Precision
$280K -$0.20 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$31.8M -$0.02 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
QDEL
QuidelOrtho
$36.51 $51.14 $2.5B -- $0.00 0% 0.88x
AEMD
Aethlon Medical
$0.43 $3.88 $6.2M -- $0.00 0% --
CATX
Perspective Therapeutics
$2.52 $15.58 $170.3M -- $0.00 0% 13.61x
VNRX
VolitionRX
$0.55 $3.37 $51M -- $0.00 0% 35.50x
VTAK
Catheter Precision
$0.42 -- $3.4M 0.48x $0.00 0% 1.12x
XTNT
Xtant Medical Holdings
$0.54 $1.75 $75.1M -- $0.00 0% 0.62x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
QDEL
QuidelOrtho
45.42% 1.384 82.87% 0.55x
AEMD
Aethlon Medical
-- -3.781 -- --
CATX
Perspective Therapeutics
-- -3.661 -- --
VNRX
VolitionRX
-28.76% -0.785 8.83% 0.19x
VTAK
Catheter Precision
12% -2.395 128.21% 0.53x
XTNT
Xtant Medical Holdings
44.29% 0.232 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
QDEL
QuidelOrtho
$326.1M $15.2M -34.12% -58.1% -13.59% $16.5M
AEMD
Aethlon Medical
-- -$1.8M -- -- -- -$2M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
VNRX
VolitionRX
-- -$5.8M -- -- -1217.88% -$5.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

QuidelOrtho vs. Competitors

  • Which has Higher Returns QDEL or AEMD?

    Aethlon Medical has a net margin of -25.21% compared to QuidelOrtho's net margin of --. QuidelOrtho's return on equity of -58.1% beat Aethlon Medical's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    QDEL
    QuidelOrtho
    46.07% -$2.28 $5.5B
    AEMD
    Aethlon Medical
    -- -$0.13 --
  • What do Analysts Say About QDEL or AEMD?

    QuidelOrtho has a consensus price target of $51.14, signalling upside risk potential of 40.08%. On the other hand Aethlon Medical has an analysts' consensus of $3.88 which suggests that it could grow by 803.26%. Given that Aethlon Medical has higher upside potential than QuidelOrtho, analysts believe Aethlon Medical is more attractive than QuidelOrtho.

    Company Buy Ratings Hold Ratings Sell Ratings
    QDEL
    QuidelOrtho
    2 3 0
    AEMD
    Aethlon Medical
    0 1 0
  • Is QDEL or AEMD More Risky?

    QuidelOrtho has a beta of 0.097, which suggesting that the stock is 90.311% less volatile than S&P 500. In comparison Aethlon Medical has a beta of 1.804, suggesting its more volatile than the S&P 500 by 80.435%.

  • Which is a Better Dividend Stock QDEL or AEMD?

    QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aethlon Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Aethlon Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios QDEL or AEMD?

    QuidelOrtho quarterly revenues are $707.8M, which are larger than Aethlon Medical quarterly revenues of --. QuidelOrtho's net income of -$178.4M is lower than Aethlon Medical's net income of -$1.8M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Aethlon Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.88x versus -- for Aethlon Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    QDEL
    QuidelOrtho
    0.88x -- $707.8M -$178.4M
    AEMD
    Aethlon Medical
    -- -- -- -$1.8M
  • Which has Higher Returns QDEL or CATX?

    Perspective Therapeutics has a net margin of -25.21% compared to QuidelOrtho's net margin of --. QuidelOrtho's return on equity of -58.1% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    QDEL
    QuidelOrtho
    46.07% -$2.28 $5.5B
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About QDEL or CATX?

    QuidelOrtho has a consensus price target of $51.14, signalling upside risk potential of 40.08%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 518.13%. Given that Perspective Therapeutics has higher upside potential than QuidelOrtho, analysts believe Perspective Therapeutics is more attractive than QuidelOrtho.

    Company Buy Ratings Hold Ratings Sell Ratings
    QDEL
    QuidelOrtho
    2 3 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is QDEL or CATX More Risky?

    QuidelOrtho has a beta of 0.097, which suggesting that the stock is 90.311% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

  • Which is a Better Dividend Stock QDEL or CATX?

    QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios QDEL or CATX?

    QuidelOrtho quarterly revenues are $707.8M, which are larger than Perspective Therapeutics quarterly revenues of --. QuidelOrtho's net income of -$178.4M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.88x versus 13.61x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    QDEL
    QuidelOrtho
    0.88x -- $707.8M -$178.4M
    CATX
    Perspective Therapeutics
    13.61x -- -- -$15.1M
  • Which has Higher Returns QDEL or VNRX?

    VolitionRX has a net margin of -25.21% compared to QuidelOrtho's net margin of -1226.82%. QuidelOrtho's return on equity of -58.1% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    QDEL
    QuidelOrtho
    46.07% -$2.28 $5.5B
    VNRX
    VolitionRX
    -- -$0.07 -$17.8M
  • What do Analysts Say About QDEL or VNRX?

    QuidelOrtho has a consensus price target of $51.14, signalling upside risk potential of 40.08%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 513.33%. Given that VolitionRX has higher upside potential than QuidelOrtho, analysts believe VolitionRX is more attractive than QuidelOrtho.

    Company Buy Ratings Hold Ratings Sell Ratings
    QDEL
    QuidelOrtho
    2 3 0
    VNRX
    VolitionRX
    2 1 0
  • Is QDEL or VNRX More Risky?

    QuidelOrtho has a beta of 0.097, which suggesting that the stock is 90.311% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

  • Which is a Better Dividend Stock QDEL or VNRX?

    QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios QDEL or VNRX?

    QuidelOrtho quarterly revenues are $707.8M, which are larger than VolitionRX quarterly revenues of $474.5K. QuidelOrtho's net income of -$178.4M is lower than VolitionRX's net income of -$5.8M. Notably, QuidelOrtho's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.88x versus 35.50x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    QDEL
    QuidelOrtho
    0.88x -- $707.8M -$178.4M
    VNRX
    VolitionRX
    35.50x -- $474.5K -$5.8M
  • Which has Higher Returns QDEL or VTAK?

    Catheter Precision has a net margin of -25.21% compared to QuidelOrtho's net margin of -4291.67%. QuidelOrtho's return on equity of -58.1% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    QDEL
    QuidelOrtho
    46.07% -$2.28 $5.5B
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About QDEL or VTAK?

    QuidelOrtho has a consensus price target of $51.14, signalling upside risk potential of 40.08%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 376.19%. Given that Catheter Precision has higher upside potential than QuidelOrtho, analysts believe Catheter Precision is more attractive than QuidelOrtho.

    Company Buy Ratings Hold Ratings Sell Ratings
    QDEL
    QuidelOrtho
    2 3 0
    VTAK
    Catheter Precision
    0 0 0
  • Is QDEL or VTAK More Risky?

    QuidelOrtho has a beta of 0.097, which suggesting that the stock is 90.311% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

  • Which is a Better Dividend Stock QDEL or VTAK?

    QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios QDEL or VTAK?

    QuidelOrtho quarterly revenues are $707.8M, which are larger than Catheter Precision quarterly revenues of $96K. QuidelOrtho's net income of -$178.4M is lower than Catheter Precision's net income of -$4.1M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.88x versus 1.12x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    QDEL
    QuidelOrtho
    0.88x -- $707.8M -$178.4M
    VTAK
    Catheter Precision
    1.12x 0.48x $96K -$4.1M
  • Which has Higher Returns QDEL or XTNT?

    Xtant Medical Holdings has a net margin of -25.21% compared to QuidelOrtho's net margin of -10.04%. QuidelOrtho's return on equity of -58.1% beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    QDEL
    QuidelOrtho
    46.07% -$2.28 $5.5B
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About QDEL or XTNT?

    QuidelOrtho has a consensus price target of $51.14, signalling upside risk potential of 40.08%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 224.07%. Given that Xtant Medical Holdings has higher upside potential than QuidelOrtho, analysts believe Xtant Medical Holdings is more attractive than QuidelOrtho.

    Company Buy Ratings Hold Ratings Sell Ratings
    QDEL
    QuidelOrtho
    2 3 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is QDEL or XTNT More Risky?

    QuidelOrtho has a beta of 0.097, which suggesting that the stock is 90.311% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

  • Which is a Better Dividend Stock QDEL or XTNT?

    QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios QDEL or XTNT?

    QuidelOrtho quarterly revenues are $707.8M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. QuidelOrtho's net income of -$178.4M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.88x versus 0.62x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    QDEL
    QuidelOrtho
    0.88x -- $707.8M -$178.4M
    XTNT
    Xtant Medical Holdings
    0.62x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Rivian a Good Stock a Buy?
Is Rivian a Good Stock a Buy?

Rivian Automotive (RIVN) had an initial IPO of close to…

Will Chevron Acquire Hess?
Will Chevron Acquire Hess?

Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…

Why Did Progressive Stock Go Down?
Why Did Progressive Stock Go Down?

Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…

Stock Ideas

Buy
56
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 36x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
47
RGC alert for Mar 25

Regencell Bioscience Holdings [RGC] is up 4.9% over the past day.

Buy
54
AZEK alert for Mar 25

The AZEK [AZEK] is up 1.01% over the past day.

Sell
36
MPTI alert for Mar 25

M-Tron Industries [MPTI] is up 7.48% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock